Transforming Oncology Trials
Recent developments in immunotherapies, such as (CAR) T-Cell therapy, illustrate virtually unprecedented long-term clinical benefits in some advanced cancer patients, and the potential for a cure seems tangible. These approaches have the potential to push the boundaries of what people thought were possible in cancer therapeutics.
ICON’s team of experts have the insights and approaches born out of our immersion in the field that make us equipped to address unique challenges in developing CAR-T trials.
Meet our experts at ASCO to discuss how these approaches can support your Oncology program and help you to get your drug to market.
Submit our short form to request a meeting with one of our experts
Sr. VP, Drug Development Services
Advising clients in drug development
Co-author of the EMA submission dossier of Paclitaxel for ovarian cancer and the FDA /EMA Taxotere submission dossier for breast cancer and NSCLC
Sr. Medical Director, Clinical Research Services
VP, Project Management, Oncology
Providing in-depth operational and indication expertise for clients in oncology drug development
VP, Development and Scientific Affairs
VP, Head of ICON Medical Imaging